Genome-wide association studies have identified approximately 200 genetic risk loci for breast cancer, but the causal variants and target genes are mostly unknown. We sought to fine-map all known ...
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN ...
Neuro-symbolic, multi-agent AI system achieves 4x faster trial matching with oncologist-confirmed accuracy across 17,000+ matches, published in ESMO Real World Data and Digital Oncology special issue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results